Tags

Type your tag names separated by a space and hit enter

Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway.
Biomed Pharmacother 2017; 96:884-891BP

Abstract

Long non-coding RNAs (lncRNAs) have been wildly verified to modulate multiple tumorigenesis, especially hepatocellular carcinoma (HCC). In present study, our team aims to investigate the role of lncRNA DLX6-AS1 in the HCC carcinogenesis. Results of early-stage experiments found that DLX6-AS1 expression level was up-regulated in 60 cases of HCC tissue samples compared with adjacent normal tissue. Moreover, the aberrant overexpression of DLX6-AS1 indicated the poor prognosis of HCC patients. Loss-of-function experiments revealed that DLX6-AS1 knockdown inhibited the proliferation, migration and invasion of HCC cells in vitro, and decreased the tumor growth in vivo. Bioinformatics analysis predicted that miR-203a potentially targeted DLX6-AS1 3'-UTR, suggesting the interaction between miR-203a and DLX6-AS1. Furthermore, miR-203a also targeted MMP-2 mRNA 3'-UTR, which was validated by luciferase reporter assay. Taken together, our study discovered the oncogenic role of DLX6-AS1 in clinical specimens and cellular experiments, showing the potential DLX6-AS1/miR-203a/MMP-2 pathway. This results and findings provide a novel insight for HCC tumorigenesis.

Authors+Show Affiliations

Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China.The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China.Operating Room, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China.Department of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China. Electronic address: andrewlee0923@163.com.Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China. Electronic address: jinzhenlin_beauty@126.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29145165

Citation

Zhang, Lei, et al. "Long Non-coding RNA DLX6-AS1 Aggravates Hepatocellular Carcinoma Carcinogenesis By Modulating miR-203a/MMP-2 Pathway." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 96, 2017, pp. 884-891.
Zhang L, He X, Jin T, et al. Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway. Biomed Pharmacother. 2017;96:884-891.
Zhang, L., He, X., Jin, T., Gang, L., & Jin, Z. (2017). Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 96, pp. 884-891. doi:10.1016/j.biopha.2017.10.056.
Zhang L, et al. Long Non-coding RNA DLX6-AS1 Aggravates Hepatocellular Carcinoma Carcinogenesis By Modulating miR-203a/MMP-2 Pathway. Biomed Pharmacother. 2017;96:884-891. PubMed PMID: 29145165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway. AU - Zhang,Lei, AU - He,Xiaowei, AU - Jin,Ting, AU - Gang,Li, AU - Jin,Zhenlin, Y1 - 2017/11/06/ PY - 2017/10/04/received PY - 2017/10/09/revised PY - 2017/10/10/accepted PY - 2017/11/18/pubmed PY - 2018/7/27/medline PY - 2017/11/18/entrez KW - DLX6-AS1 KW - Hepatocellular carcinoma KW - Long non-coding RNA KW - MMP-2 KW - miR-203a SP - 884 EP - 891 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed. Pharmacother. VL - 96 N2 - Long non-coding RNAs (lncRNAs) have been wildly verified to modulate multiple tumorigenesis, especially hepatocellular carcinoma (HCC). In present study, our team aims to investigate the role of lncRNA DLX6-AS1 in the HCC carcinogenesis. Results of early-stage experiments found that DLX6-AS1 expression level was up-regulated in 60 cases of HCC tissue samples compared with adjacent normal tissue. Moreover, the aberrant overexpression of DLX6-AS1 indicated the poor prognosis of HCC patients. Loss-of-function experiments revealed that DLX6-AS1 knockdown inhibited the proliferation, migration and invasion of HCC cells in vitro, and decreased the tumor growth in vivo. Bioinformatics analysis predicted that miR-203a potentially targeted DLX6-AS1 3'-UTR, suggesting the interaction between miR-203a and DLX6-AS1. Furthermore, miR-203a also targeted MMP-2 mRNA 3'-UTR, which was validated by luciferase reporter assay. Taken together, our study discovered the oncogenic role of DLX6-AS1 in clinical specimens and cellular experiments, showing the potential DLX6-AS1/miR-203a/MMP-2 pathway. This results and findings provide a novel insight for HCC tumorigenesis. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/29145165/Long_non_coding_RNA_DLX6_AS1_aggravates_hepatocellular_carcinoma_carcinogenesis_by_modulating_miR_203a/MMP_2_pathway_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(17)35154-5 DB - PRIME DP - Unbound Medicine ER -